Drug Trial Radar · NCT01494688
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
217
Actual
Start
Dec 20, 2011
Primary completion
Feb 7, 2018
Study completion Feb 7, 2018
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, multicenter, dose-escalation study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of RO5509554 in participants with advanced solid tumors which are not amenable to standard treatment. In Part I (Dose Escalation), multiple ascending doses of RO5509554 will be administered as monotherapy in participants with solid tumors. Participants with locally advanced and/or metastatic ovarian (including fallopian tube) and breast carcinoma will receive multiple ascending doses of RO5509554 in combination with paclitaxel. In Part II (Expansion Cohort), RO5509554 will be administered as monotherapy to participants with locally advanced and/or metastatic Pigmented Villonodular Synovitis (PVNS)/Tenosynovial Giant Cell Tumor (TGCT), soft tissue sarcoma or malignant mesothelioma, ovarian (including fallopian tube), endometrial or breast cancer and pancreatic cancer. Participants with Human Epidermal Growth Factor Receptor 2 (HER2)/neu negative breast cancer will receive RO5509554 in combination with paclitaxel. Anticipated time on study treatment is until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
Conditions
- Advanced Solid Tumors
Interventions
PaclitaxelDrug
Paclitaxel, at a dose of 80 mg/m\^2 will be administered QW for up to 12 weeks.
RO5509554Drug
RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse EventsTime frame: Baseline up to 28 days after last dose (approximately 48 months)
- Part 1: Maximum Tolerated Dose (MTD)/Optimal Biological Dose (OBD) of RO5509554 as a Single Agent and in Combination With PaclitaxelTime frame: Cycle 1 Day 1 (cycle length = 14 or 21 days) up to 28 days
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center
New York, New York
Univ of Pennsylvania Med Ctr
Philadelphia, Pennsylvania
Institut Bergonie; Oncologie
Bordeaux, France
Centre Leon Berard; Departement Oncologie Medicale
Lyon, France
Institut Curie; Oncologie Medicale
Paris, France
Ico Rene Gauducheau; Oncologie
Saint-Herblain, France
Institut Claudius Regaud; Departement Oncologie Medicale
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.